BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 11992778)

  • 21. Binding, domain orientation, and dynamics of the Lck SH3-SH2 domain pair and comparison with other Src-family kinases.
    Hofmann G; Schweimer K; Kiessling A; Hofinger E; Bauer F; Hoffmann S; Rösch P; Campbell ID; Werner JM; Sticht H
    Biochemistry; 2005 Oct; 44(39):13043-50. PubMed ID: 16185072
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Experimental and calculated shift in pK(a) upon binding of phosphotyrosine peptide to the SH2 domain of p56(lck).
    de Mol NJ; Gillies MB; Fischer MJ
    Bioorg Med Chem; 2002 May; 10(5):1477-82. PubMed ID: 11886810
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structure of the regulatory domains of the Src-family tyrosine kinase Lck.
    Eck MJ; Atwell SK; Shoelson SE; Harrison SC
    Nature; 1994 Apr; 368(6473):764-9. PubMed ID: 7512222
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
    Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T
    Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors.
    Zhu X; Kim JL; Newcomb JR; Rose PE; Stover DR; Toledo LM; Zhao H; Morgenstern KA
    Structure; 1999 Jun; 7(6):651-61. PubMed ID: 10404594
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Crystal structure analysis and solution studies of human Lck-SH3; zinc-induced homodimerization competes with the binding of proline-rich motifs.
    Romir J; Lilie H; Egerer-Sieber C; Bauer F; Sticht H; Muller YA
    J Mol Biol; 2007 Feb; 365(5):1417-28. PubMed ID: 17118402
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design and synthesis of small chemical inhibitors containing different scaffolds for lck SH2 domain.
    Park SH; Kang SH; Lim SH; Oh HS; Lee KH
    Bioorg Med Chem Lett; 2003 Oct; 13(20):3455-9. PubMed ID: 14505648
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck I.
    Arnold LD; Calderwood DJ; Dixon RW; Johnston DN; Kamens JS; Munschauer R; Rafferty P; Ratnofsky SE
    Bioorg Med Chem Lett; 2000 Oct; 10(19):2167-70. PubMed ID: 11012021
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recognition of a high-affinity phosphotyrosyl peptide by the Src homology-2 domain of p56lck.
    Eck MJ; Shoelson SE; Harrison SC
    Nature; 1993 Mar; 362(6415):87-91. PubMed ID: 7680435
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibitory effects of rosmarinic acid on Lck SH2 domain binding to a synthetic phosphopeptide.
    Ahn SC; Oh WK; Kim BY; Kang DO; Kim MS; Heo GY; Ahn JS
    Planta Med; 2003 Jul; 69(7):642-6. PubMed ID: 12898421
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structure-based design and synthesis of high affinity tripeptide ligands of the Grb2-SH2 domain.
    Furet P; Gay B; Caravatti G; García-Echeverría C; Rahuel J; Schoepfer J; Fretz H
    J Med Chem; 1998 Aug; 41(18):3442-9. PubMed ID: 9719597
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck II.
    Burchat AF; Calderwood DJ; Hirst GC; Holman NJ; Johnston DN; Munschauer R; Rafferty P; Tometzki GB
    Bioorg Med Chem Lett; 2000 Oct; 10(19):2171-4. PubMed ID: 11012022
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimization of 2-phenylaminoimidazo[4,5-h]isoquinolin-9-ones: orally active inhibitors of lck kinase.
    Goldberg DR; Butz T; Cardozo MG; Eckner RJ; Hammach A; Huang J; Jakes S; Kapadia S; Kashem M; Lukas S; Morwick TM; Panzenbeck M; Patel U; Pav S; Peet GW; Peterson JD; Prokopowicz AS; Snow RJ; Sellati R; Takahashi H; Tan J; Tschantz MA; Wang XJ; Wang Y; Wolak J; Xiong P; Moss N
    J Med Chem; 2003 Apr; 46(8):1337-49. PubMed ID: 12672234
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Conformationally constrained phosphotyrosyl mimetics designed as monomeric Src homology 2 domain inhibitors.
    Burke TR; Barchi JJ; George C; Wolf G; Shoelson SE; Yan X
    J Med Chem; 1995 Apr; 38(8):1386-96. PubMed ID: 7537333
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hydrophobic D-amino acids in the design of peptide ligands for the pp60src SH2 domain.
    Plummer MS; Lunney EA; Para KS; Prasad JV; Shahripour A; Singh J; Stankovic CJ; Humblet C; Fergus JH; Marks JS; Sawyer TK
    Drug Des Discov; 1996 Apr; 13(3-4):75-81. PubMed ID: 8874045
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tyrosine phosphorylation-dependent activation of NF-kappa B. Requirement for p56 LCK and ZAP-70 protein tyrosine kinases.
    Livolsi A; Busuttil V; Imbert V; Abraham RT; Peyron JF
    Eur J Biochem; 2001 Mar; 268(5):1508-15. PubMed ID: 11231305
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Src homology-2 domains (SH2 domains) of the protein tyrosine kinase p56lck: structure, mechanism and drug design.
    Broadbridge RJ; Sharma RP
    Curr Drug Targets; 2000 Dec; 1(4):365-86. PubMed ID: 11467076
    [TBL] [Abstract][Full Text] [Related]  

  • 38. N-(3-(phenylcarbamoyl)arylpyrimidine)-5-carboxamides as potent and selective inhibitors of Lck: structure, synthesis and SAR.
    Deak HL; Newcomb JR; Nunes JJ; Boucher C; Cheng AC; DiMauro EF; Epstein LF; Gallant P; Hodous BL; Huang X; Lee JH; Patel VF; Schneider S; Turci SM; Zhu X
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1172-6. PubMed ID: 18083554
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modular folding and evidence for phosphorylation-induced stabilization of an hsp90-dependent kinase.
    Hartson SD; Ottinger EA; Huang W; Barany G; Burn P; Matts RL
    J Biol Chem; 1998 Apr; 273(14):8475-82. PubMed ID: 9525961
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ligands for the tyrosine kinase p56lck SH2 domain: discovery of potent dipeptide derivatives with monocharged, nonhydrolyzable phosphate replacements.
    Beaulieu PL; Cameron DR; Ferland JM; Gauthier J; Ghiro E; Gillard J; Gorys V; Poirier M; Rancourt J; Wernic D; Llinas-Brunet M; Betageri R; Cardozo M; Hickey ER; Ingraham R; Jakes S; Kabcenell A; Kirrane T; Lukas S; Patel U; Proudfoot J; Sharma R; Tong L; Moss N
    J Med Chem; 1999 May; 42(10):1757-66. PubMed ID: 10346928
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.